ClinicalTrials.gg
RecruitingNCT07158242AMETRINE-PEDSUpdated Nov 5, 2026

A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis

A Phase 3 interventional study of Afimkibart in Moderately to Severely Active Ulcerative Colitis, sponsored by Hoffmann-La Roche. Recruiting at 29 sites in 9 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.
Updated Nov 5, 20267 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
2 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies in Colitis, Ulcerative by Hoffmann-La Roche — 4 open to participants now, 6 under way, 4 of them phase 3. Colitis, Ulcerative · Hoffmann-La Roche.

Planned enrollment
16th of 24
100 · median 169
Started
2026
with 2 others
Phase 3
10 of 24
2 open now
Registered
22nd of 24
by date

Among the 24 studies in Colitis, Ulcerative by Hoffmann-La Roche, this one is the 16th largest by planned enrollment, is one of 3 that started in 2026, is one of 10 in phase 3, and was the 22nd registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

4 of the 24 studies in Colitis, Ulcerative by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 2 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Colitis, Ulcerative by Hoffmann-La Roche, or all of them as a file.
02

Study summary

This Phase III, randomized, double-blind, multicenter, induction and maintenance study will evaluate the safety and efficacy of Afimkibart (RO7790121) in pediatric participants with moderate to severe active ulcerative colitis (UC).

03

Conditions studied

  • Moderately to Severely Active Ulcerative Colitis

Browse trials for

04

Who can participate

Ages eligible
2 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Bodyweight >= 10 kilogram (kg)
  • Confirmed diagnosis of UC
  • Moderately to severely active UC, defined as modified Mayo Score (mMS) or 5 to 9 points, including endoscopic score of 2 or 3, confirmed by centrally read endoscopy (flexible sigmoidoscopy or colonoscopy)
  • Demonstrated intolerance or inadequate response (IR) to one or more of the following categories of drugs: systemic , immunomodulators, and/or biologic therapies as outlined in the protocol

Exclusion criteria

Exclusion Criteria:

  • Monogenic disorder pertaining to infant onset inflammatory bowel disease (IBD)
  • Current diagnosis of Crohn's disease (CD), abdominal/intrabdominal/perianal fistula and/or abscess, indeterminant colitis, IBD-unclassified, microscopic colitis, ischemic colitis, infectious colitis, radiation colitis, or active diverticular disease
  • Presence of an ostomy or ileoanal pouch
  • Current diagnosis or suspicion of primary sclerosing cholangitis
  • Any major surgery within 6 weeks prior to screening or a major planned surgery during the study
  • Active tuberculosis (TB) infection suggested by positive TB testing, clinical symptoms, and/or chest imaging (X-ray or CT)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Afimkibart Dose A

    Participants will receive Afimkibart intravenously (IV) followed by Afimkibart subcutaneous (SC) injection.

    Drug: Afimkibart

  • Experimental
    Afimkibart Dose B

    Participants will receive Afimkibart IV followed by Afimkibart SC.

    Drug: Afimkibart

Interventions

  • Afimkibart will be administered as IV infusion. Afimkibart will be administered as SC injection.

    Also known as: PF-06480605, RVT-3101, RG6631, RO7790121

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Clinical Remission at Week 52

    Time frame: At Week 52

Secondary outcomes

  1. Change From Baseline in Pediatric Ulcerative Colitis Activity Index (PUCAI) Response

    Time frame: From Baseline, at Week 12

  2. Percentage of Participants With PUCAI Remission

    Time frame: At Week 12

  3. Change From Baseline in Tummy Ulcerative Colitis (TUMMY-UC) Scores

    Time frame: From Baseline to Week 12

  4. Partial Modified Mayo Score (pmMS)

    Time frame: At Week 12

  5. Percentage of Participants With Symptomatic Response

    Time frame: At Week 12

  6. Percentage of Participants With Symptomatic Remission

    Time frame: At Week 12

  7. Change From Baseline in PUCAI Response at Week 52

    Time frame: From Baseline, at Week 52

  8. Percentage of Participants With PUCAI Remission at Week 52

    Time frame: At Week 52

  9. Change From Baseline in TUMMY-UC Scores

    Time frame: From Baseline to Week 52

  10. Percentage of Participants With Endoscopic Remission

    Time frame: At Week 52

  11. Percentage of Participants With Endoscopic Improvement

    Time frame: At Week 52

  12. Percentage of Participants With Histologic Improvement

    Time frame: At Week 52

  13. Percentage of Participants With Histologic-endoscopic Mucosal Improvement

    Time frame: At Week 52

  14. Percentage of Participants With Histologic-endoscopic Mucosal Remission

    Time frame: At Week 52

  15. Percentage of Participants With Clinical Remission Without the use of Corticosteroids

    Time frame: At Week 52

  16. Percentage of Participants With Adverse Events (AEs)

    Time frame: From Baseline up to approximately 4 years

  17. Serum Concentration of Afimkibart

    Time frame: Up to approximately 4 years

07

Study locations

29 of 29 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Mar 2030, 47 months after the start.

Of 87 industry-sponsored phase 3 interventional studies under Colitis, Ulcerative, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 70. This study's planned 47 months is close to that.

Counting every sponsor, half of 101 studies reached it within 48 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2025
First posted
Sep 5, 2025
StartActual
Apr 15, 2026
Primary completionEst.
Mar 31, 2030
CompletionEst.
Mar 31, 2031
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
7 sites added
Show 7 added (5 United States, 1 Brazil, 1 United Kingdom)
  • Connecticut Children's Medical Center · Hartford, United States
  • Washington University · St Louis, United States
  • UPMC Childen?s Hospital of Pittsburgh · Pittsburgh, United States
  • Santa Casa de Misericordia de Porto Alegre · Porto Alegre, Brazil
  • Cleveland Clinic;Children's Institute · Cleveland, United States
  • Texas Digestive Specialists · Harlingen, United States
  • Great North Children's Hospital · Newcastle upon Tyne, United Kingdom
across 2 updates, Oct 6, 2026 – Nov 5, 2026
Show all 2 updates
  1. Nov 5, 2026
    3 sites added
    Show 3 added (2 United States, 1 United Kingdom)
    • Cleveland Clinic;Children's Institute · Cleveland, United States
    • Texas Digestive Specialists · Harlingen, United States
    • Great North Children's Hospital · Newcastle upon Tyne, United Kingdom
    + 1 other change: verification date
  2. Oct 6, 2026
    4 sites added
    Show 4 added (3 United States, 1 Brazil)
    • Connecticut Children's Medical Center · Hartford, United States
    • Washington University · St Louis, United States
    • UPMC Childen?s Hospital of Pittsburgh · Pittsburgh, United States
    • Santa Casa de Misericordia de Porto Alegre · Porto Alegre, Brazil
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07158242
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Sep 5, 2025
Start date
Apr 15, 2026
Primary completion
Mar 31, 2030 (estimated)
Completion
Mar 31, 2031 (estimated)
Last update
Nov 5, 2026

Study contacts

Reference Study ID Number: CA45905 https://forpatients.roche.com/ No attachments to email below.
Contact
global-roche-genentech-trials@gene.com
888-662-6728 (U.S. and Canada)
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Contact
Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Afimkibart

Start the discussion